MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
In Vivo
Parents
*Key Terms: Biotechnology
BioTechnology
Children
- In Vivo Targeted Degradation of HIV Proteins
* Company’s integrated product engine overcomes limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery.
* It has developed the MIRA (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device, focusing first on colon resection, with follow-on specialty robots for additional potential applications.
*Architects: Biosensors_Wearables, Remote Patient Monitoring (RPM), PERS, Fall Detection, SMART Pills Companies
*Architects: Biotechnology _ Gene Editing, CRISPR, Etc.
*Architects: Biotechnology _ Natural Killer (NK) Cells
*Architects: Biotechnology_Genetics, Gene & Cell Therapy Companies
*Architects: Diagnostics_In Vivo
*Architects: Diagnostics_Infectious Disease, Food, Environmental & Biodefense
*Architects: Human Factors, Human Performance, Human Computer Interfaces (HCI) / Brain Computer Interfaces (BCI) Companies
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars, Technology) _ TBI
*Biosimulation software can replace in vivo (human) clinical trials - in certain cases - with in silico trials.
*Capstan’s modular platform leverages the biological and technological expertise of its founding scientists and includes proprietary targeted lipid nanoparticles (tLNP) technology, a suite of targeting moieties to mediate cell type-specific uptake, and disease-specific mRNA payloads aimed at directly engineering, or ablating pathogenic cells through in vivo generated CAR T cells
*Developing and delivering precise in vivo cell engineering to patients
*Empowering Cells In Vivo to Fight Cancer
*Funding: Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD)
*Funding: Diagnostics_In Vivo
*Funding: HIV/AIDS & STD (Sexually Transmitted Disease)
*Funding: NIH_NIDCD
*Funding: NIH_NINDS
*Funding: NIH_Office of Strategic Coordination (Common Fund)
*nChroma Bio is developing in vivo targeted genetic medicine to treat a wide array of diseases
*Platform develops chimeric antigen receptor T cells directly in vivo bypassing the need for ex vivo cell manipulations required for standard CAR T-cell treatments
*Sana was founded to create a platform to develop cell engineering technologies, for both in vivo and ex vivo therapies
*SNA technology overcomes the most difficult obstacles to gene regulation: genetic targeting with safe and effective in vivo performance.
*Vivos Therapeutics Inc. is a research and development company that provides training for dentists and health care providers, enabling them to integrate craniofacial sleep medicine into their practice
*YOLT-204 is an off-the-shelf in vivo gene editing therapy developed for TDT without conditioning chemotherapy and HSCT. YOLT-204 delivers a gene editor to hematopoietic stem cells through YolTech's proprietary lipid nanoparticles.
*YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines.
$45 million financing led by Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation.
1) New plasmid-bax gene vector, and test for bax expression in transfected C6 cells in vitro and in vivo,
1) Optimize ex vivo adenovirus-mediated gene transfer to corneal endothelial cells during hypothermic organ preservation using t
1) Test existing OCT ex vivo & compare with histology
2. To apply the chemometric methods developed for use with the IFOP in an in vivo clinical setting to assess the degree of artic
2010: National Institute of Mental Health (NIMH) awards a Phase I SBIR grant to MicroTransponder to develop a neurostimulation-based therapy to treat Post Traumatic Stress Disorder-PTSD (2010)
2014: Funding supports expansion of company VivoSight multi-beam OCT imaging system sales in Germany, where it is reimbursed for use in diagnosing non-melanoma skin cancer (NMSC) since 2011 (2014)
2018: A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS
2018: NIDA_In Vivo Electrophysiology and Integrated Video Behavioral Tracking System
2018: NIDA_In Vivo Electrophysiology and Integrated Video Behavioral Tracking System
2018: NIDA_Maintenance Services for PerkinElmer in vivo Micro CT Scanner
2019: The latest series C round included several new backers such as Aisling Capital Management, Pentwater Capital Management and Perceptive Advisors. Poseida’s previous investors—Longitude Capital, Malin Corporation, Vivo Capital and Boxer Capital—also participated.
2020: Lead Investor Vivo Capital is Joined by Avoro Capital Advisors, Funds, accounts Managed by BlackRock, Deerfield Management CompanyandOrbiMed
2020: MPM, DCVC Bio back $53M round for a bold concept_Let patients make their own CAR-T in vivo
2020: Series C capital round of $50 million, led by HLM Venture Partners, one of the top healthcare venture firms in the country, along with participation from new investors Commonfund and Vivo Capital, and existing investors Toba Capital, Transformation Capital, and Silicon Valley Bank
2020: Series D round was led by DFJ Growth, with additional backing from Vivo Capital, Mithril Capital Management, Norwest Venture Partners, Section 32 and robotic surgery pioneer Fred Moll, co-founder of Intuitive Surgical and Auris Health
2020: The capital, drawn from Remiges Ventures, SR One, Vivo Capital, Hillsborough Venture and Correlation Ventures
2020: The Series B round was led by Cormorant Asset Management, venBio Partners, Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital, Aisling Capital, Vertex Ventures, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners.
2020: Vivos Therapeutics Pursues $20 Million IPO_seekingalpha
2021: Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online
2021: Intellia Expands Its In Vivo Advantage
2021: Investors in the firm have invested at least $332 million and include Curative Ventures, Vivo Capital, CPMG and Venrock
2021: Investors in the firm have invested at least $95 million and include Lilly Asia Ventures (LLY), OrbiMed Advisors, Vivo Capital and Deerfield Partners.
2021: NINDS_NOIP_Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
2021: The drug discovery company uses its ATX-Gx in vivo human antibody discovery platform, currently employed by more than 70 life sciences teams in biopharma and academia, and its setup to “democratize” research by making access easier and cheaper.
2021: The most advanced project has demonstrated in vivo efficacy superior to benchmarks as presented at the American Academy of Cancer Research last year and repeated in multiple models.
2021: The Series A financing round was led by Matrix Partners China and US-based Vivo Capital
2021: The series B funding round was led by Logos Capital with participation from venBio Partners, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital.
2022: Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering
2022: Engineered synthesis, processing, and in-vivo performance of multicancer drug nanocapsules_Georgia Southern University
2022: FDA_Investigating the In Vivo Behavior and In Vitro Characteristics of a Purportedly Gastro-Retentive Extended Release Formulation to Elucidate Considerations Relevant to Generic Products (U01) Clinical Trials Required
2022: Golub Capital banked the company's 2021 merger with $65 million in growth funding, bringing its total commitment in the last year to more than $137 million. Other investors include CommonFund, HLM Venture Partners, OpenView Venture Partners, StepStone Group, Stripes Group, Montreux Equity Partners, Toba Capital, Transformation Capital and Vivo Capital.
2022: Intellia: In-Vivo Gene Editing Platform Continues To Deliver_ seekingalpha.com
2022: NIDA_Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)
2022: NIMH_NOIP_Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
2022: Portable In-Vivo Oxidative Stress (IVOS) Biosensor_University of Adelaide
2022: UPDATED: Intellia presents a promising snapshot of its first data for once-and-done in vivo CRISPR treatment for HAE
2022: Vivos Therapeutics: First Take After The Broad Market Sell-Off_seekingalpha.com
2023: Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision
2023: FDA_In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required
2023: NIAID_New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed)
2023: NINDS_Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in TBI-related dementia and/or VCID (U24
2023: Vivos bounces back from FDA rejection to land 510(k) clearance for sleep apnea treatment
2024: Editas prioritizes in vivo gene therapies, looks to partner reni-cel
2024: First Patient Dosed with In Vivo Gene Therapy for CAR T
2024: Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
2024: Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
2024: NIA_NOSI_In vivo Synaptic Function in Alzheimer's Disease and Related Dementias
2024: NIMH_Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
2024: NINDS_Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in ARIA (U24
2024: The private placement is being led by new investor, Venrock Healthcare Capital Partners, and includes significant participation by new and existing life sciences-focused investors, including RA Capital Management, TCGX, BVF Partners LP, Vivo Capital, Spruce Street Capital, Adage Capital Partners LP, and Checkpoint Capital.
2024: Topic 002 Development of novel In-vitro and In-vivo Models to support NeuroHIV Research
2025: NIDA_Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
2025: NIDCD_Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)
2025: NIDCD_In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)
2025: NIH_Common Fund_In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed
2025: NIMH_Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
2025: NIMH_Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
2025: Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
2025: Received FDA Fast Track designation for troculeucel, its ex vivo expanded autologous NK cell therapy for moderate Alzheimer’s disease.
2025: YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
2026: NCI_Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
2026: NIMH_Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
2027: NIDCD_NOSI: Development of Imaging Techniques for High Resolution and Functional Scanning of In Vivo Human Sensory and Communication Systems
2DG has acute anticonvulsant actions in multiple in vivo and in vitro preclinical seizure models.
3) Test hand-held probe by imaging in vivo pig model
Ability to produce/modify transplantable cells outside the body (ex vivo).
Backed by Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures
BioMarker Strategies is focused on the development of their SnapPath™ex vivo biomarker platform to guide and improve the treatment of cancer.
Blood supply to developing tissue-engineered structures in vivo.
can potently activate T cells both in vitro and in vivo
Cellectis BioResearch SA (NASDAQ: CLLS)
Center for In Vivo Microscopy, Duke
Commercial-stage specialty contract research organization providing small animal in vivo multi-modality imaging services
Company has developed in vivo optical imaging systems that enables real-time, noninvasive imaging of internal tissue microstructure
Core platform technology, which was already validated in-vivo, enables permanent implants to bio-mechanically integrate with live tissue without triggering an adverse immune system response.
Corneal endothelium does not normally regenerate in vivo
CranioSense, a subsidiary of Vivonics, Inc.
demonstrate that human corneal endothelial cells transplanted in vitro can be grown to densities that are comparable to in vivo
develop a HIV vector with insulator elements optimized for prolonged in vivo gene expression
development of a new diagnostic device to precisely locate fluorescence in-vivo
Development of a Novel In Vivo Recombinant Protein Delivery Device Designed to Regress Abnormal Tissue-CIMIT
Development of Light Scattering-based In Vivo Flow Cytometry
Development of Methods for In Vivo Imaging and Bioengineering Research, NIH
Development-stage biotechnology company focused on in vivo recombination manufacturing technologies
Device to non-invasively detect and monitor blood borne disease in vivo, without taking blood
Dissociated fragments of human donor tissue will spontaneously reiterate in vivo organogenesis if given adequate culture conditi
Editas Medicine, Inc. (NASDAQ:EDIT)*
Elucid Bioimaging Inc.
ExVivo Dynamics
FDA _ Regenerative Medicine Advanced Therapy (RMAT)
Finance & Acquisitions: Vivonics
Finance & Acquisitions: Vivos
Garmin Vivofit
Genocea can rapidly identify antigens that result in the in vivo stimulation of protective CD8+ and CD4+ T-cells
Gilead Sciences, Inc. (NASDAQ: GILD)*
High Throughput In Vivo Dynamic Metabolic Assay Using an Embryonic Development Model-University of Arizona
Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders.
Hypothesis:in vitro engineered organogenesis reiterates in vivo organogenesis at the molecular level.
Immunovaccine
Implantable Nanoparticle-Based Sensor for In Vivo Optical Monitoring of Analytes -NMTB
In Vivo Blog
In vivo Detection of Inflamed Plaques in Rabbits Using FDG and a Novel Beta-Detecting Catheter -CIMIT
IN VIVO Europe Rx
In vivo evolution of an RNA-based transcriptional activator-Harvard University Office of Technology Development
In Vivo Imaging
In Vivo Imaging of Normal Rodent Mammary Gland
in vivo Molecular Imaging, November 17-20, 2008 • San Diego, CA
In Vivo Pressure Measurement System
In vivo therapeutic monitoring
In vivo tissue bioprobe to help women get pregnant, automatically detecting pregnancy and any early pregnancy loss, with additio
IN VIVO: The Business and Medicine Report
In-Vivo Fiberoptic Probe for Intra-operative Fluorescence Quantification in Tissue-University Health Network
Intellia Therapeutics Inc. (NASDAQ:NTLA)*
Interius BioTherapeutics, Inc.
Investor(s) Teknoinvest, Vivo Ventures
Investors: Prospect Venture Partners, US Venture Partners, Vivo Capital
Investors: Vivo Ventures, Fidelity Biosciences
Josh Berlin – @BioPharmaToday: Exec Editor w/Elsevier, publisher of The Pink Sheet, IN VIVO and PharmAsia News
Key People: Vivonics
Key People: Vivos
Kristian DiMatteo, Vivonics
Lifeshirt by VivoMetrics
Light scattering based in vivo flow cytometry (LSIVFC)
Measurement of disease progression in vivo using noninvasive biosensors.
Melior Discovery
Meridian Bioscience (NASDAQ:VIVO)
Methods and Devices for Ex VIvo Irridation of Autologous Coronary Bypass Conduit-Emory University
microscopic resolution (~10 microns) with extremely high sensitivity in vivo
Miniature In Vivo Robots for Tele-Surgery in Forward Environments - U of Nebraska
Moderna, Inc. (NASDAQ:MRNA)*
Molecular imaging is the in vivo visualization of cellular processes at the molecular level
molecular imaging technologies that allow in vivo imaging using novel markers provides great promise
New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners
NIEHS has awarded one-year SBIR grant to Vivo Biosceinces (PI: Dr. Raj Singh)for developing a 3D human liver bioassay system to monitor long-term drug toxicity
NLS offers services in pharmacology, disease models, early safety assessments, toxicology, PCR, Flow Cytometry, in vivo imaging, and cell-based assays
Non-Invasive In Vivo Pressure Measurement-Children's Hospital Boston
Non-invasive technique for quantitative monitoring of circulating cells in vivo.
noninvasive monitoring of glucose levels in vivo glucose
Organization & Developments: Vivonics
Organization & Developments: Vivos
Part of DARPA's goal to develop an ex-vivo immune system
Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.
PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic.
Physiologically based pharmacokinetic (PBPK) models are an effective tool to integrate information about the product characteristics, the physiology of the individual subject, and the variability among subjects within a population to simulate the absorption and subsequent systemic disposition of the drug without conducting in vivo pharmacokinetic studies.
Pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo.
Primary research interests lie in the field of in vivo molecular imaging.
PuraMatrix gels consist of smart polymers, self-assembling in cell culture or in vivo to create biocompatible nanofiber scaffolds to facilitate healthy cell growth and tissue regeneration
PuraMatrix, a peptide hydrogel synthetic matrix material to create three-dimensional micro-environments for various cell culture and in vivo experiments, as well as for tissue regeneration, cell therapies, and drug delivery system applications
Real-time, in vivo `optical biopsy `
Skin physiology, skin/device interface, and novel assay development, Seventh Sense is creating a unique "On Vivo™" blood sampling and testing platform.
Spotlight Therapeutics is a venture funded early-stage biotechnology company with a mission to develop a new class of therapeutics by enabling direct in vivo gene editing.
Texcell is a service provider for the pharmaceutical and biotech companies, with 4 key activities: viral detection (viral safety) & viral clearance, custom cell culture & GMP banking, immunology and in vivo testing.
The company's flagship product is the VivoSight OCT scanner, which produces high definition images of the layers of the skin and subsurface features, allowing physicians and dermatologists to make accurate treatment decisions
The Nexus 128 makes in vivo quantification of tumor vasculature possible without the need for contrast agents and helps preclinical researchers gain deeper insight into areas such as how drugs treat disease and cancer progression, without ionizing radiatio
The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics.
The purpose of this contract is to conduct, develop, acquire, improve, implement, validate, analyze and report data from state-of-the-art high-throughput functional omics assays and approaches (e.g., genomics, epigenomics, transcriptomics, proteomics) for comprehensive characterization of immune responses in samples from in vivo or in vitro studies investigating simian immunodeficiency virus (SIV), simian-human immunodeficiency virus (SHIV), HIV and other infectious diseases
The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo.
The purpose of this NOFO is to provide support for applications for IND-enabling studies for the development of a novel in vivo genome editing therapeutic platform (genome editor plus delivery system) for two or more disease indications, using the same genome editor, route of administration, and delivery system.
The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ( validated hits ) for chemical optimization and bioassays for testing new analog compounds.
The purpose of this notice of special interest (NOSI) for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants (Phase 1 or Phase 2) is to advance and accelerate the future clinical translation of RNA-based therapeutics to treat or prevent human diseases using non-viral technologies. To accomplish this goal, the NOSI will support the pre-clinical testing and evaluation of non-viral technologies to deliver RNA-based therapeutics or RNA-based vaccines to disease-relevant somatic cells and tissues in vivo.
The purpose of this notice of special interest (NOSI) for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants (Phase 1 or Phase 2) is to advance and accelerate the future clinical translation of RNA-based therapeutics to treat or prevent human diseases using non-viral technologies. To accomplish this goal, the NOSI will support the pre-clinical testing and evaluation of non-viral technologies to deliver RNA-based therapeutics or RNA-based vaccines to disease-relevant somatic cells and tissues in vivo.
The Seventh Sense On Vivo™ platform will enable diagnostic testing to be performed safely and painlessly by virtually anyone, anywhere.
The therapy is administered in ex vivo form.
The unique properties of these medicines include tissue targeting beyond the liver, repeatable dosing with sustained expression, tunable in vivo immunomodulation, and multiple routes of administration – creating new frontiers for mRNA therapeutics and vaccines, with further potential to transform the gene editing and protein-based therapy landscapes as well.
These devices are used to perform in vivo imaging of small animals as well as in vitro studies.
They are dedicated to solving the immune response issues that limit the safety and efficacy of in vivo gene therapies.
This NOFO invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms underlying the interaction between addictive substances and HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC).
This notice of funding opportunity (NOFO) aims to encourage research grant applications for initial translational efforts that will enable a drug discovery program for novel, non-opioid, and non-addictive treatments for pain. The program provides funding to develop and validate assays to support a distinct testing funnel and conduct screening efforts to identify and characterize potential therapeutic agents including small molecules, biologics, and natural products. Preliminary in vivo pharmacokinetic, pharmacodynamic, and efficacy studies may also be supported. The goal of this NOFO is to advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program or other later-stage translational programs.
This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the scaling up of brain cell type-specific molecular or genetic access reagents to study circuit function. Scaled engineering and validation of cell type-specific reagents are priorities to be supported. Applications are sought for Reagent Resource for Design and Development projects that scale up the creation of these tools for several vertebrate species, including in experimental animals and human ex vivo tissues or cells. Projects will integrate: scaled engineering, validation, cataloguing, and adaptation into easily disseminable formats of reagents.
This Notice of Funding Opportunity (NOFO) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) in the development of a new, or optimization of an existing, in vivo and/or in vitro high-throughput screening (HTS) platform for use in identifying potential compounds for treating alcohol use disorder (AUD).
This Notice of Funding Opportunity (NOFO) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) in the development of a new, or optimization of an existing, in vivo and/or in vitro high-throughput screening (HTS) platform for use in identifying potential compounds for treating alcohol use disorder (AUD).
Ulrich Dauer, PHD CEO, VIVORYON THERAPEUTICS N.V. (2021)
Umoja Biopharma is pioneering the use of immunotherapy for solid tumors by reprogramming T cells in vivo, rather than ex vivo, using CAR-T cell therapy
Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer
Unlike companies that offer their sensor with a limited and static software tool, VivoSense is a single software solution designed to be compatible with any physiological sensor.
VaxNewMo is an early stage biotechnological company developing next-generation conjugate vaccines against infectious diseases using our proprietary in vivo conjugating technology
VisEn is pioneering a new era of in vivo imaging.
Vivo Biosciences
Vivo Ventures
Vivonics Inc.
Vivonoetics has already developed custom VivoSense algorithms for research programs being conducted at a number of prestigious academic, medical and government institutions
VivoQuest
Vivoryon Therapeutics
Vivoryon Therapeutics has product candidates in both clinical and preclinical development and are focusing on age-related diseases with unmet medical need.
Vivos Therapeutics, Inc. (NASDAQ: VVOS)*
VivoSense provides clinical researchers an accurate, thorough and objective evaluation of biologic states in a clinical or ambulatory setting.
VivoSense, Inc., also known as Vivonoetics
VivoSight uses the company's multi-beam OCT technology to noninvasively view all the layers of the skin in real time and in high definition.
With participation from leading medical personnel, engineers and entrepreneurs, ElectroSonix is currently focused on designing, building, and validating the first in vivo acoustoelectric cardiac imaging (ACI) system for real-time mapping of arrhythmias with sub-mm precision.
Jumps
In Vitro